![]() ![]() These four resins together provide a toolbox approach that covers purification of nearly all Fabs fragments and a majority of smaller antibody fragments. These resins can be used without the need for lengthy process development or optimization. In the white paper, the authors describe a platform purification approach that is comprised of four different resins, each of which provides a platform solution for a specific type of antibody fragment. To better understand antibody fragments, their production and purification, my research led me to a very interesting white paper, “A Platform Approach to Purification of Antibody Fragments”, by GE Healthcare. Bi-specific antibodies combine two antigen binding regions into a single therapeutic, such as Blincyto ®.Īntibody fragments are also being explored for use in antibody drug conjugates where a full length antibody or an antibody fragment is linked to a cytotoxic agent designed to kill target cells when internalized and released antibody gene therapy applications and antibody fragments are also being linked with liposomes or nanoparticles to improve drug delivery. Several antibody fragments have been approved and are commercially available, including: ReoPro®, Lucentis®, and Cimzia®.Īntibody fragment-based therapeutics also include bi-specific antibodies. Antibody fragments have some advantages over full-length antibodies and several antibody fragment-based biotherapeutics are in clinical research. ![]() Due to the multi-domain structure of antibodies, it is possible to create smaller antibody fragments that still include the antigen-binding domain. While there are many new monoclonal antibodies in the clinical trial pipeline, there are also some innovative drugs made from just an antibody fragment. Since the 1980’s monoclonal antibodies have revolutionized medicine and become a vital tool in fighting many diseases. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |